Shenzhen Kangtai Biological Products (300601.SZ)

Overall impact
B (71)

Commentary

Shenzhen Kangtai Biological Products is a strong overall performer. With a 'B' rating of 71.0 for overall impact (84th percentile compared to all companies), Shenzhen Kangtai Biological Products ranks 49th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 45 others, and ahead of Assertio Therapeutics, Evolus, DiaMedica Therapeutics and 102 others. On top material causes for Shenzhen Kangtai Biological Products's industry (Pharmaceuticals & Biotech), Shenzhen Kangtai Biological Products performs well in Disease Eradication (96.4 score), Technology Innovation (90.4), Access to Affordable Healthcare (86.6) and 1 other cause where it received an 'A' score. Shenzhen Kangtai Biological Products did not receive a 'D' or 'F' rating on any cause.
Impact
Cause 300601.SZ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Shenzhen Kangtai Biological Products

Employees
1,957
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
300601.SZ
Description
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. Its marketed vaccines include SARS-COV-2 vaccines, HIB conjugate vaccines, 13-valent pneumococcal conjugate vaccines, recombinant hepatitis B vaccines, 23-valent pneumococcal polysaccharide vaccines, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccines, cell-free whitebait b-type haemophilus influenzae combined vaccines, and measles and rubella combined vaccines. The company's research and development vaccines comprise rabies vaccine for human use, inactivated poliomyelitis vaccine, and live attenuated varicella vaccine. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Material causes
Ethos considers the following causes material for Shenzhen Kangtai Biological Products, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.